Earnings Summary

Hookipa Pharma Inc.’s revenue fell -5.38% since last year same period to $7.41Mn in the Q4 2023. On a quarterly growth basis, Hookipa Pharma Inc. has generated 7.86% jump in its revenue since last 3-months.

Hookipa Pharma Inc.’s net profit fell -97.91% since last year same period to $-24.82Mn in the Q4 2023. On a quarterly growth basis, Hookipa Pharma Inc. has generated -30.17% fall in its net profits since last 3-months.

Hookipa Pharma Inc.’s net profit margin fell -109.16% since last year same period to -335.06% in the Q4 2023. On a quarterly growth basis, Hookipa Pharma Inc. has generated -20.68% fall in its net profit margins since last 3-months.

Hookipa Pharma Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.1 - a 47.37% jump from last quarter’s estimates.

Hookipa Pharma Inc.’s earning per share (EPS) estimates for the current year stand at -0.1.

Hookipa Pharma Inc.’s earning per share (EPS) fell -29.41% since last year same period to -0.22 in the Q4 2023. This indicates that the Hookipa Pharma Inc. has generated -29.41% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Hookipa Pharma Inc.’s return on assets (ROA) stands at -0.32.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Hookipa Pharma Inc.’s return on equity (ROE) stands at -0.85.